Most of the molecular glue degraders in clinical development co-opt cereblon (CRBN), a substrate recognition receptor for the CRL4 E3 ligase complex, to induce the ubiquitination and degradation ...

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review ...

A key differentiator is pomalidomide’s unique ability to degrade ARID2 (a PBAF complex subunit), which suppresses MYC expression and overcomes lenalidomide resistance (Yamamoto et al., 2020).